Company Directory / research
PrivateFor profitresearchWatertown, United States
Dyno Therapeutics
Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
- Founded
- 2018 8 years ago
- Staff
- 101-250 band, as listed
- Followers
- - on LinkedIn
- Funding
- $109M as listed, currency not stated
Set against six million companies
Size
101-250 people: larger than 85% of companies with a size listed
Age
8 years old.
Reach
Website ranked #8,305,523 in the world for traffic, about 577 visits a month.
What it does
Artificial Intelligence (AI)BiotechnologyHealth Care
Funding, as listed
$109M currency not stated
- Rounds3
- LatestSeries a, May 2021
- Investors9, 3 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Dyno Therapeutics, field by field. Contact details are held but never shown.
The company
- Name
- Dyno Therapeutics
- Type
- For profit
- Status
- Private
- Founded
- 2018
- Founders
- Adrian Veres, Alan Crane, Eric Kelsic, George Church, Sam Sinai, Tomas Bjorklund
- Industry
- research
- Categories
- Artificial Intelligence (AI), Biotechnology, Health Care
Where
- City
- Watertown
- Country
- United States
- Markets
- Greater Boston Area, East Coast, New England, Northeastern US
Size and reach
- Staff band
- 101-250
- Web traffic rank
- #8,305,523
- Monthly web visits
- 577
Funding, as listed
- Total
- 109,000,000 (currency not stated)
- Rounds
- 3
- Latest round
- Series a
- Latest round date
- May 2021
- Investors
- 9
- Lead investors
- 3
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Dyno Therapeutics may be growing as the company is actively participating in significant industry events, which is indicative of its engagement with the scientific community and potential for establishing its presence in the biotechnology sector. The company's involvement in the ASGCT Annual Congress and the SynBioBeta Global Synthetic Biology Conference suggests that it is contributing to the discourse on AI methods for AAV capsid design, which could enhance its reputation and lead to increased opportunities for collaboration or funding. Although the provided article does not include explicit financial numbers or details on revenue, funding, or employee headcount, the act of presenting at prestigious conferences is often associated with companies that are making strides in their field and looking to expand their influence.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in United States.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.